Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Channing J Der

Showing results (191-200 of 236) with videos related to

Pageof 24
Sort By:
Cancer Research|November 7, 2023
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C InhibitorsA Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, et al.
Molecular Cancer Therapeutics|March 5, 2022
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell CarcinomaSehrish Javaid, Antje Schaefer, Craig M Goodwin, et al.
Cancer Research|February 20, 2007
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanomaJaniel M Shields, Nancy E Thomas, Melissa Cregger, et al.
Cancer Research|December 18, 2021
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy InhibitorsClint A Stalnecker, Kajal R Grover, A Cole Edwards, et al.
Pharmacology Research & Perspectives|August 5, 2022
Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpPEmily M J Fennell, Lucas J Aponte-Collazo, Joshua D Wynn, et al.
Science Signaling|September 28, 2017
Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodiesAndrew M Waters, Irem Ozkan-Dagliyan, Angelina V Vaseva, et al.
Science Signaling|July 18, 2019
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancerDevon R Blake, Angelina V Vaseva, Richard G Hodge, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor ResistanceKristina Drizyte-Miller, Seamus E Degan, Ryan D Mouery, et al.
The Journal of Biological Chemistry|October 24, 2021
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancerJ Nathaniel Diehl, Jennifer E Klomp, Kayla R Snare, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerWen-Hsuan Chang, Alec J Vaughan, Addison G Stamey, et al.
Pageof 24

Showing results (191-200 of 236) with videos related to

Sort By:
Pageof 24
Cancer Research|November 7, 2023
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C InhibitorsA Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, et al.
Molecular Cancer Therapeutics|March 5, 2022
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell CarcinomaSehrish Javaid, Antje Schaefer, Craig M Goodwin, et al.
Cancer Research|February 20, 2007
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanomaJaniel M Shields, Nancy E Thomas, Melissa Cregger, et al.
Cancer Research|December 18, 2021
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy InhibitorsClint A Stalnecker, Kajal R Grover, A Cole Edwards, et al.
Pharmacology Research & Perspectives|August 5, 2022
Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpPEmily M J Fennell, Lucas J Aponte-Collazo, Joshua D Wynn, et al.
Science Signaling|September 28, 2017
Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodiesAndrew M Waters, Irem Ozkan-Dagliyan, Angelina V Vaseva, et al.
Science Signaling|July 18, 2019
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancerDevon R Blake, Angelina V Vaseva, Richard G Hodge, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor ResistanceKristina Drizyte-Miller, Seamus E Degan, Ryan D Mouery, et al.
The Journal of Biological Chemistry|October 24, 2021
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancerJ Nathaniel Diehl, Jennifer E Klomp, Kayla R Snare, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerWen-Hsuan Chang, Alec J Vaughan, Addison G Stamey, et al.
Pageof 24